Pan-Cancer Efficacy of Vemurafenib in BRAF ^V600-Mutant Non-Melanoma Cancers.

ABSTRACT: BRAF ^V600 mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers. Despite this progress, BRAF ^V600 mutations have historically been considered a clear demonstration of tumor lineage context-dependent oncogene addiction, based predominantly on the insensitivity to RAF inhibition in colorectal cancer. However, the true broader activity of RAF inhibition pan-cancer remains incompletely understood. To address this, we conducted a multicohort "basket" study of the BRAF inhibitor vemurafenib in non-melanoma BRAF ^V600 mutation-positive solid tumors. In total, 172 patients with 26 unique cancer types were treated, achieving an overall response rate of 33% and median duration of respons

SUBMITTER: Subbiah V 

PROVIDER: S-EPMC7196502 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature